Standout Papers

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose... 2010 2026 2015 2020 643
  1. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity (2010)
    Wyndham H. Wilson, Owen A. O’Connor et al. The Lancet Oncology
  2. Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease (2011)
    Andrew W. Roberts, John F. Seymour et al. Journal of Clinical Oncology

Immediate Impact

4 by Nobel laureates 12 from Science/Nature 63 standout
Sub-graph 1 of 20

Citing Papers

Targeting protein–ligand neosurfaces with a generalizable deep learning tool
2025 StandoutNature
Frailty in Older Adults
2024 Standout
3 intermediate papers

Works of Yue Cui being referenced

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
2011 Standout
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
2010 Standout

Author Peers

Author Last Decade Papers Cites
Yue Cui 167 151 315 858 400 55 1.8k
Carl E. Freter 64 116 379 1022 509 52 2.2k
Attilio Guarini 63 107 446 544 596 108 2.0k
David T. Yang 93 101 636 1027 758 90 2.6k
Christopher Ocampo 165 104 219 922 574 33 2.1k
Luke Coyle 100 88 157 363 331 45 1.5k
Roger Strair 55 87 323 773 418 67 1.6k
Germana Castelli 86 76 225 1604 766 93 3.0k
Jay N. Lozier 127 186 149 912 418 65 2.6k
Richard L. Humphrey 27 177 177 681 297 59 1.7k
Mark D. Rothmann 48 70 155 430 432 44 1.7k

All Works

Loading papers...

Rankless by CCL
2026